Search

CN-116615180-B - Hydroxyapatite composition for the treatment and/or prevention of viral infections

CN116615180BCN 116615180 BCN116615180 BCN 116615180BCN-116615180-B

Abstract

The present invention relates to a composition comprising hydroxyapatite for use in the treatment and/or prevention of viral infections.

Inventors

  • Eric Schulze Zullweishen
  • Miriam Stark
  • Edward Richard Dornberg

Assignees

  • 库特沃夫博士有限及两合公司

Dates

Publication Date
20260512
Application Date
20210924
Priority Date
20200924

Claims (20)

  1. 1. Use of a composition comprising 0.01 to 5wt% of hydroxyapatite in the manufacture of a reagent for the treatment and/or prophylaxis of enveloped virus infection, Wherein the composition further comprises 1wt% or less of a surfactant, wherein the surfactant comprises a mixture of surfactant A, surfactant B and surfactant C, wherein the surfactant A is an alkyl sulfate and is present in the composition in an amount of 0.1 to 0.9 wt%, the surfactant B is an alkyl taurate and is present in the composition in an amount of 0.01 to 0.2 wt%, and the surfactant C is an alkyl sarcosinate and is present in the composition in an amount of 0.001 to 0.06 wt%; The composition further comprises 0.01 to 0.5wt% of a water soluble zinc salt selected from the group consisting of zinc L-pyrrolidone carboxylate, zinc acetate, zinc chloride, zinc histidine, zinc gluconate, zinc aspartate, zinc citrate, zinc sulfate, zinc lactate, and mixtures thereof, and The agent is a mouthwash or aerosol.
  2. 2. The use according to claim 1, wherein the composition further comprises 0.001 to 5wt% of a polyol selected from the group consisting of erythritol, arabitol, lactitol, maltitol, mannitol, sorbitol, xylitol and mixtures thereof.
  3. 3. The use according to claim 1, wherein the surfactant a is sodium dodecyl sulfate, the surfactant B is sodium methyl cocoyl taurate, and the surfactant C is sodium myristoyl sarcosinate.
  4. 4. Use according to claim 2, wherein the polyol is sorbitol and/or xylitol.
  5. 5. The use according to any one of claims 1 to 4, wherein the composition comprises no ethanol or comprises 0.001 to 60wt% ethanol.
  6. 6. The use according to any one of claims 1 to 4, wherein the composition further comprises 0.001 to 5wt% of a component selected from eucalyptol, thymol, menthol, anise oil, fennel oil and left menthol.
  7. 7. The use according to any one of claims 1 to 4, wherein the composition comprises transferrin.
  8. 8. The use of claim 7, wherein the composition comprises lactoferrin.
  9. 9. The use according to any one of claims 1 to 4, wherein the composition further comprises a film forming polymer selected from the group consisting of carrageenan, carboxymethyl cellulose (CMC) and pharmaceutically acceptable salts thereof, hydroxypropyl methylcellulose (HPMC), ethyl cellulose, methyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, hyaluronic acid and pharmaceutically acceptable salts thereof, copolymers of methyl vinyl ether and maleic acid and pharmaceutically acceptable salts thereof, carboxymethyl chitin, polyvinylpyrrolidone, chitosan, and mixtures thereof.
  10. 10. The use according to any one of claims 1 to 4, wherein the composition further comprises a water insoluble zinc salt.
  11. 11. The use according to any one of claims 1 to 4, wherein the agent is formulated for administration to a mucosa.
  12. 12. The use of claim 11, wherein the agent is formulated for application to a mucosa by a spray device.
  13. 13. The use according to any one of claims 1 to 4, wherein the virus belongs to the family coronaviridae.
  14. 14. The use according to claim 13, wherein the virus is SARS-CoV-2.
  15. 15. A composition comprising 0.01 To 5wt% of hydroxyapatite, 0.01 To 0.5wt% of a water soluble zinc salt selected from the group consisting of zinc L-pyrrolidone carboxylate, zinc acetate, zinc chloride, zinc histidine, zinc gluconate, zinc aspartate, zinc citrate, zinc sulfate, zinc lactate and mixtures thereof, Less than or equal to 1wt% of a surfactant, wherein the surfactant comprises a mixture of surfactant A, surfactant B, and surfactant C, the surfactant A is an alkyl sulfate having a level of from 0.1 to 0.9 wt% in the composition, the surfactant B is an alkyl taurate having a level of from 0.01 to 0.2 wt% in the composition, the surfactant C is an alkyl sarcosinate having a level of from 0.001 to 0.06 wt% in the composition, and 0.001 To 5wt% of a polyol selected from the group consisting of erythritol, arabitol, lactitol, maltitol, mannitol, sorbitol, xylitol and mixtures thereof, Wherein the composition is a mouthwash or aerosol.
  16. 16. The composition of claim 15, wherein the surfactant a is sodium dodecyl sulfate, the surfactant B is sodium methyl cocoyl taurate, and the surfactant C is sodium myristoyl sarcosinate.
  17. 17. The composition of claim 15, wherein the polyol is sorbitol and/or xylitol.
  18. 18. The composition of any one of claims 15 to 17, wherein the composition does not comprise ethanol or comprises 0.001 to 60wt% ethanol.
  19. 19. The composition of any one of claims 15 to 17, wherein the composition further comprises 0.001 to 5wt% of a component selected from the group consisting of eucalyptol, thymol, menthol, anise oil, fennel oil, and left menthol.
  20. 20. The composition of any one of claims 15 to 17, wherein the composition comprises transferrin.

Description

Hydroxyapatite composition for the treatment and/or prevention of viral infections Technical Field The present invention relates to a composition for the treatment and/or prevention of viral infections comprising 0.001 to 40wt. -% of hydroxyapatite. Background Viruses belonging to the family coronaviridae (Coronaviridae) were first characterized in the 60s of the 20 th century. Viral infections belonging to this family are common in all mammals, including humans. The outbreak of SARS-CoV-2 suggests that new pharmaceutical compositions are needed to treat and prevent a wide range of viral infections, particularly SARS-CoV-2 infections. Coronaviruses are RNA viruses with linear ss-RNAs (single-stranded RNAs), transmitted by droplet infection, resulting in fever and respiratory problems. Several species are relatively harmless, causing only acute and mild symptoms or producing asymptomatic courses of disease (HCoV-OC 43, 229E, HKU1 and HL 63). On the other hand, SARS-CoV (Severe acute respiratory syndrome coronavirus), MERS-CoV (middle east respiratory syndrome coronavirus) and SARS-CoV-2 are coronaviruses that can cause severe respiratory and pulmonary infections. To date, there are very limited therapeutic or prophylactic regimens other than exposure prevention. The anti-SARS-CoV-2 activity of some mouthwash compositions has been studied in vitro by Meister et al (MEISTER ET al, the Journal of Infectious Diseases 2020,222, pp 1289-1292). Disclosure of Invention In view of the above, it is an object of the present invention to provide a new, safe and effective composition for the treatment and/or prophylaxis of viral infections in general, and in particular for the treatment and prophylaxis of SARS-CoV-2 infection. These objects have surprisingly been solved by a composition comprising 0.001 to 40wt. -% hydroxyapatite. Surprisingly, it was found that according to the above aspects, the infectious virus can be prevented, or at least the probability of infection can be significantly reduced. Furthermore, according to the above aspect, the virus count in the respiratory tract is significantly reduced, so that the infected person is no longer infectious to the third person. In another aspect, the invention relates to a composition comprising: 0.001 to 40wt. -% of hydroxyapatite, 0.001 To 20wt. -% of a water-soluble zinc salt selected from the group consisting of zinc L-pyrrolidone carboxylate, zinc acetate, zinc chloride, zinc histidine, zinc gluconate, zinc aspartate, zinc citrate, zinc sulfate, zinc lactate and mixtures thereof, 0.001 To 5wt. -% of an anionic surfactant, and 0.001 To 5wt. -% of a polyol selected from the group consisting of erythritol, arabitol, lactitol, maltitol, mannitol, sorbitol, xylitol and mixtures thereof. The invention also relates to a kit of parts comprising a composition of the invention and a spraying device, a mouthwash device or a rinsing device for applying the composition to the mucosa of the nose, mouth (oral) and/or throat (pharyngeal). Detailed Description The following definitions relate to embodiments of the invention. The term "comprising" shall be construed to cover all the specifically mentioned features as well as optional, additional, unspecified features, whereas the term "consisting of" only includes the specified features. Accordingly, the inclusion of a composition specified by the term composition is intended to be limiting. The term "weight-%" or "wt. -%" is to be understood as meaning the weight of the components relative to the total weight of the corresponding composition, if not specified otherwise. The term "water soluble" refers to zinc salts having a solubility of 0.1g/L or greater under standard conditions. Accordingly, the term "water insoluble" refers to zinc salts having a solubility of less than 0.1g/L under standard conditions, i.e., at a temperature of 15 ℃ and a pH of 7.0. The term "film-forming" polymer refers to a polymer that forms a tacky continuous layer when applied to a surface. In the present invention, the film-forming polymer results in the formation of a tie layer of the composition that further enhances the adhesive properties to the mucosa when the composition is applied topically to the mucosa. As used herein, in one aspect, the term "preventing" a viral infection (also referred to as prophylaxis) refers to preventing a (local) infection in a subject that has been exposed to the virus. On the other hand, the term "preventing" also refers to preventing infection to other subjects in case the subject using the composition has been infected with a virus. In other words, the composition is generally effective in preventing viral infection and/or further transfer or distribution of viruses, e.g., by aerosol/droplet transmission. Thus, a dual approach to preventing the broad spread of viruses is achieved by the compositions of the present invention. According to the present invention, "treatment" and "prevention" of viral infection is base